atorvastatin has been researched along with Diabetic Cardiomyopathies in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amour, J; Biais, M; Birenbaum, A; Bonnefont-Rousselot, D; Cagnard, N; Carillion, A; Carpentier, W; Feldman, S; Hatem, S; Loyer, X; Na, N; Riou, B | 1 |
| Eleftheriadou, I; Grigoropoulou, P; Katsilambros, N; Makrilakis, K; Margeli, A; Papassotiriou, I; Perrea, D; Tentolouris, N; Zoupas, C | 1 |
| Abdel-Hamid, AA; Firgany, Ael-D | 1 |
| Chen, SL; Hu, ZY; Luo, J; Ren, XM; Wu, W; Ye, P; Zuo, GF | 1 |
| Aguilar, C; Rodríguez-Delfín, L; Ventura, F | 1 |
1 trial(s) available for atorvastatin and Diabetic Cardiomyopathies
| Article | Year |
|---|---|
Effect of atorvastatin on baroreflex sensitivity in subjects with type 2 diabetes and dyslipidaemia.
Topics: Aged; Atorvastatin; Baroreflex; Body Mass Index; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Diet, Fat-Restricted; Dyslipidemias; Female; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myalgia; Obesity; Patient Dropouts; Prospective Studies; Pyrroles; Risk Factors | 2014 |
4 other study(ies) available for atorvastatin and Diabetic Cardiomyopathies
| Article | Year |
|---|---|
Atorvastatin reduces β-Adrenergic dysfunction in rats with diabetic cardiomyopathy.
Topics: Animals; Atorvastatin; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Echocardiography; Heart; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Contraction; Myocardium; Myocytes, Cardiac; Papillary Muscles; Rats; Rats, Wistar; Receptors, Adrenergic, beta | 2017 |
Atorvastatin alleviates experimental diabetic cardiomyopathy by suppressing apoptosis and oxidative stress.
Topics: Animals; Apoptosis; Atorvastatin; Biomarkers; Blood Glucose; Caspase 3; Diabetic Cardiomyopathies; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Malondialdehyde; Myocardium; Myocytes, Cardiac; Oxidation-Reduction; Oxidative Stress; Rats | 2015 |
Atorvastatin Alleviates Experimental Diabetic Cardiomyopathy by Regulating the GSK-3β-PP2Ac-NF-κB Signaling Axis.
Topics: Animals; Apoptosis; Atorvastatin; Catalytic Domain; Cell Line; Diabetic Cardiomyopathies; Glucose; Glycogen Synthase Kinase 3 beta; I-kappa B Kinase; Male; Mice, Inbred C57BL; Myocytes, Cardiac; NF-kappa B; Protein Phosphatase 2; Rats, Sprague-Dawley; Signal Transduction | 2016 |
[Atorvastatin induced increase in homologous angiotensin I converting enzyme (ACE2) mRNA is associated to decreased fibrosis and decreased left ventricular hypertrophy in a rat model of diabetic cardiomyopathy].
Topics: Animals; Atorvastatin; Diabetic Cardiomyopathies; Disease Models, Animal; Fibrosis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Male; Peptidyl-Dipeptidase A; Pyrroles; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2011 |